CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

J Joseph M. Rocco (1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) J Joseph H. Oved (2Pediatric Transplant and Cellular Therapy Service, Memorial Sloan Kettering Kids, Memorial Sloan Kettering Cancer Center, New York, NY) R Rikita J. Patel (3Department of Medicine, New York–Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY) A A. Zara Herskovits (4Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) N Namitha Nair (5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA) B Bita Shakoory (1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) T Thomas E. Robertson (6Medicine Institute, Allegheny Health Network, Pittsburgh, PA) R Rachel Dileo (6Medicine Institute, Allegheny Health Network, Pittsburgh, PA) M Max W. Jacobs (6Medicine Institute, Allegheny Health Network, Pittsburgh, PA) C Christa S. Zerbe (Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health) R Rachael A. Gordon (5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA) M Michael J. Ombrello (7National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD) A Amanda K. Ombrello (8National Human Genome Research Institute, National Institutes of Health, Bethesda, MD) N Nirali N. Shah D Dimana Dimitrova J Jennifer Kanakry (10Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD) A Andrew D. Zelenetz (11Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) A Alison J. Moskowitz (3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) R Robert Stuver (3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) Z Zachary D. Epstein-Peterson (11Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) P Paola Ghione (4Memorial Sloan Kettering Cancer Center, New York, NY) E Elena Mead (12Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) Z Zainab Shahid (13Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) S Sandeep Raj (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) J Jae H. Park S Sergio A. Giralt (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York) I Ivan Maillard M Mark B. Geyer (Memorial Sloan Kettering Cancer Center) W Wenbin Xiao A Ahmet Dogan (Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York) M Megan Lim J Jeffrey I. Zwicker (5Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY) J Jodi Mones (18Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) R Rehka Parameswaran (18Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) L Lauren Banaszak (16Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) S Shamir Geller (19Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) B Bianca D. Santomasso (12Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) R Roni Shouval (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) K Kevin J. Curran O Ottavia Delmonte (1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) L Luigi D. Notarangelo J Jeffrey I. Cohen (2Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) S Steven M. Holland G Gilles Salles (41Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY) S Steven M. Horwitz (Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York) S Santosha A. Vardhana (11Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) M Miguel-Angel Perales (1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY) D Daniella Schwartz (5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA) I Irini Sereti W William T. Johnson (1Lymphoma Service and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY)

Abstract

Abstract Hemophagocytic lymphohistiocytosis (HLH) is an interferon gamma–driven hyperinflammatory syndrome with high morbidity and mortality. Identifying reliable prognostic biomarkers is challenging due to various predisposing conditions and triggers. C-X-C-motif ligand 9 (CXCL9) is a clinically validated biomarker and surrogate marker of interferon gamma–mediated inflammation. We aimed to identify the role of CXCL9 in predicting severe disease and death in adults with HLH using a multicenter retrospective cohort of consecutively hospitalized patients who underwent a clinical evaluation for HLH that included CXCL9 testing. Patients were classified as HLH if they met HLH-2004 and/or HScore criteria. Conditional inference decision trees and Cox regression models were used to identify which clinical variables associated with acute mortality in patients with HLH. Overall, 171 patients were reviewed, and 126 patients met HLH criteria. The median age was 55 years (interquartile range, 40-66), with 62% male and 51% White. CXCL9 was markedly elevated in patients with HLH. Unbiased decision tree modeling, incorporating all clinical laboratory values, identified only CXCL9 of >16 100 pg/mL as the optimal predictor of inpatient mortality. Cox regression models demonstrated that CXCL9 of >16 100 pg/mL was significantly associated with 90-day mortality when controlling for important covariates. This shorter time to death in the elevated CXCL9 subgroup remained significant even after subdividing patients into those with malignancy (n = 53) and nonmalignancy HLH (n = 73). Continuous increases in CXCL9 within the cohort strongly associated with greater mortality. CXCL9 is a novel clinical marker that identifies high-risk HLH independent of underlying disease and could be used to select patients for early and aggressive targeted immunomodulatory therapy.

Article Details

Journal Blood
Volume / Issue Vol. 147, Issue 9
Published February 26, 2026
Pages 960-972
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (50)

J

Joseph M. Rocco

1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

J

Joseph H. Oved

2Pediatric Transplant and Cellular Therapy Service, Memorial Sloan Kettering Kids, Memorial Sloan Kettering Cancer Center, New York, NY

R

Rikita J. Patel

3Department of Medicine, New York–Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY

A

A. Zara Herskovits

4Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

N

Namitha Nair

5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

B

Bita Shakoory

1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

T

Thomas E. Robertson

6Medicine Institute, Allegheny Health Network, Pittsburgh, PA

R

Rachel Dileo

6Medicine Institute, Allegheny Health Network, Pittsburgh, PA

M

Max W. Jacobs

6Medicine Institute, Allegheny Health Network, Pittsburgh, PA

C

Christa S. Zerbe

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health

R

Rachael A. Gordon

5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

M

Michael J. Ombrello

7National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

A

Amanda K. Ombrello

8National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

N

Nirali N. Shah

D

Dimana Dimitrova

J

Jennifer Kanakry

10Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD

A

Andrew D. Zelenetz

11Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

A

Alison J. Moskowitz

3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

R

Robert Stuver

3Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Z

Zachary D. Epstein-Peterson

11Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

P

Paola Ghione

4Memorial Sloan Kettering Cancer Center, New York, NY

E

Elena Mead

12Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Z

Zainab Shahid

13Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

S

Sandeep Raj

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

J

Jae H. Park

S

Sergio A. Giralt

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

I

Ivan Maillard

M

Mark B. Geyer

Memorial Sloan Kettering Cancer Center

W

Wenbin Xiao

A

Ahmet Dogan

Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York

M

Megan Lim

J

Jeffrey I. Zwicker

5Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY

J

Jodi Mones

18Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

R

Rehka Parameswaran

18Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

L

Lauren Banaszak

16Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

S

Shamir Geller

19Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

B

Bianca D. Santomasso

12Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

R

Roni Shouval

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

K

Kevin J. Curran

O

Ottavia Delmonte

1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

L

Luigi D. Notarangelo

J

Jeffrey I. Cohen

2Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD

S

Steven M. Holland

G

Gilles Salles

41Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

S

Steven M. Horwitz

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

S

Santosha A. Vardhana

11Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

M

Miguel-Angel Perales

1Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

D

Daniella Schwartz

5Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

I

Irini Sereti

W

William T. Johnson

1Lymphoma Service and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY